Full-Time

Learning Program Manager

Posted on 9/11/2026

Deadline 10/31/26
Sanofi

Sanofi

10,001+ employees

Global pharma company; vaccines and R&D

No salary listed

Hyderabad, Telangana, India

Remote

Travel is required as needed by business needs.

MBA

Category
People & HR (1)
Required Skills
SharePoint

Get referred to Sanofi

See people who can refer or advise you

Requirements
  • 10+ years of experience in learning and pharma, or 3+ years of relevant experience.
  • Ability to manage stakeholders and build effective working relationships with different stakeholders.
  • Ability to communicate effectively and work independently and within a team environment.
  • Business skills including communication, resource and risk management, decision-making, logical thinking, negotiation, leadership, and debate.
  • Project management experience, with facilitation and presentation skills.
  • Excellent spoken and written English.
  • MBA or equivalent degree from a reputed business school.
Responsibilities
  • Support projects and initiatives focused on the adoption, execution, and management of learning and development programs.
  • Coordinate programs that enhance employee capabilities through continuing education and skills training.
  • Collaborate with leaders and colleagues to drive program buy-in and adoption by communicating program purpose, value, competencies, goals, development needs, and strategic initiatives.
  • Create strategies and design, manage, implement, monitor, and evaluate learning and development programs, processes, and initiatives.
  • Create, support, and execute learning strategies and programs.
  • Coordinate document translations and manage weekly or biweekly communications to global colleagues.
  • Coordinate certificate completion, gamification, and post-webinar attendance activities.
  • Coordinate with vendors, consultants, and subject matter experts to maintain learning program content and update it as best practices evolve.
  • Maintain the learning schedule and events calendar and lead program event logistics, including agenda scheduling, audience interaction, material and supply orders, feedback, and pre- and post-session engagement.
  • Follow the instructional design process from needs assessment through evaluation to develop one-on-one, group, and e-learning curricula, videos, interactive e-modules, and gamification.
  • Manage projects and processes involving learning metrics and learning technology, including e-learning strategy and document repository strategy.
  • Track and report project and program milestones.
  • Plan and orchestrate webinars and develop, post, and maintain content on SharePoint sites or other suitable repositories.
  • Manage team meetings, including minutes, logistics, and follow-up.
  • Develop and maintain team procedures and user documentation.
  • Manage learning activities such as workshops and gamification programs.
  • Act as a learning program liaison and conduct program evaluation.
  • Develop communication plans and establish supporting infrastructure.
  • Develop and execute communication strategies and content through email, Microsoft Teams, Yammer, and video diaries.
  • Coordinate communication and learning program translations.
  • Support vendor management for learning development, deployment, and communications.
  • Work with project coordinators to manage the centralized mailbox, respond to daily inquiries, and distribute standard responses.
  • Manage the FAQ communication document through monthly reviews of common issues and questions and update it accordingly.
  • Manage certificate completion, gamification, post-webinar attendance, Zoom and workshop activities, and LXP/LMS learning-plan design and governance.
  • Use leadership and team input to plan, develop, customize, and implement materials, instructional content, and delivery mechanisms for different audiences and functional groups.
  • Partner with subject matter experts to ensure consistent delivery of training and deliverables.
Desired Qualifications
  • Project Management or Scrum Master certification.

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2026 sales rose 13.6%, while launches grew 49.6% and Dupixent 30.8%.
  • July 2026 FDA approval expanded Sarclisa across all U.S. myeloma indications.
  • Paulo Fontoura assumed R&D leadership on September 1, 2026, accelerating pipeline execution.

What critics are saying

  • Tolebrutinib’s FDA rejection on December 24, 2025 exposed severe liver-injury risk.
  • Dupixent lawsuits consolidated in New Jersey by June 2026 threaten label and damages exposure.
  • Sanofi’s insulin plant needed €400 million German aid on September 8, 2026, signaling supply fragility.

What makes Sanofi unique

  • Dupixent posted €4.17 billion Q1 2026 sales, dominating immunology globally.
  • Sanofi’s July 2026 Sarclisa Escena became the first cancer on-body injector treatment.
  • Sanofi secured Cenrifki EU approval in June 2026, advancing a differentiated MS franchise.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Parental Leave

Company News

La Croix
Sep 8th, 2026
EU approves $448M German subsidy to Sanofi for insulin production security

The European Commission has approved a €400 million subsidy from Germany to pharmaceutical company Sanofi to maintain its Frankfurt insulin production site. The Commission stated that without this aid, Sanofi would close the German facility, reducing insulin supply security across the European Economic Area. The subsidy aims to compensate Sanofi for costs related to a service of general economic interest, strengthening insulin supply resilience for German patients. In return, Sanofi must build a new insulin factory in Frankfurt by 31 December 2032 and guarantee minimum annual production of 1.1 tonnes until 2042. Sanofi is among the world's leading insulin producers. The company announced in 2024 a €1.3 billion investment in Frankfurt to construct a new complex replacing existing facilities.

StreetInsider
Aug 25th, 2026
Altesa BioSciences wins award for oversubscribed $75M Series B to advance COPD therapies

Atlanta-based Altesa BioSciences has won the 2026 Georgia Life Sciences Golden Helix Award for Deal of the Year, recognising its oversubscribed $75 million Series B financing round. The funding, led by Forbion with participation from Sanofi, Medicxi, Pitango, and Atlantic Partners, will advance the clinical-stage pharmaceutical company's lead therapy, vapendavir. Vapendavir is an investigational oral treatment for chronic lung diseases including COPD and asthma. The drug is currently being evaluated in the Phase 2b CARDINAL trial, which will enrol 900 COPD patients across the US and UK. The Georgia Research Alliance Venture Fund was an early investor in Altesa. The company's scientific founders previously helped develop molnupiravir, one of the earliest COVID-19 treatments.

Business Wire
Aug 13th, 2026
Epicrispr Biotechnologies Closes $90 Million Oversubscribed Series C Financing to Advance First-in-Class Epigenetic Therapy Toward Pivotal Studies in FSHD

Epicrispr Biotechnologies Closes $90 Million Series C Financing to Advance First-in-Class Epigenetic Therapy Toward Pivotal Studies in FSHD

Morningstar
Aug 12th, 2026
InduPro raises $77M Series B, doses first patient in Phase 1 trial of bispecific ADC for lung cancer

InduPro has closed a $77 million Series B financing round and dosed its first patient in a Phase 1 study of IDP-001, its lead oncology programme. The biotechnology company is developing IDP-001, a bispecific antibody-drug conjugate targeting EGFR and a novel tumour-associated proximity antigen, for treating advanced squamous non-small cell lung cancer and other solid tumours. The Column Group led the financing round, with participation from Vida Ventures, MRL Ventures Fund, Emerson Collective, Euclidean Capital, Solasta Ventures, Sanofi, and Eli Lilly and Company. Proceeds will support Phase 1 clinical development and early proof-of-concept data generation for IDP-001, whilst advancing InduPro's broader preclinical pipeline. InduPro uses a proximity-guided platform to map protein spatial relationships on cell surfaces for discovering selective co-target pairs.

FinancialContent
Jul 24th, 2026
Scribe Therapeutics prices upsized $129M IPO at top of range

Scribe Therapeutics, a clinical-stage biotechnology company developing in vivo CRISPR technologies, has priced its upsized initial public offering at $15.00 per share, the high end of its range. The company is offering 8,580,000 shares, expecting to raise $128.7 million in gross proceeds before fees and expenses. Scribe has also granted underwriters a 30-day option to purchase up to 1,287,000 additional shares. The shares are expected to begin trading on the Nasdaq Global Market on 24 July 2026 under the ticker symbol "SCTX", with the offering closing on 27 July 2026. Additionally, Scribe has agreed to sell 500,000 shares at the same price to Sanofi in a concurrent private placement. Leerink Partners, Goldman Sachs, Guggenheim Securities, and Wells Fargo Securities are serving as joint book-running managers.